Charles Zhu
Stock Analyst at LifeSci Capital
(3.24)
# 1,045
Out of 4,711 analysts
24
Total ratings
47.62%
Success rate
16.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.32 | - | 1 | Dec 13, 2024 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $3.10 | +158.06% | 3 | Nov 7, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $3.18 | +277.36% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $41.85 | +14.70% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $84.22 | -33.51% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.39 | +308.16% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $7.84 | +231.63% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $25.61 | +24.95% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $14.14 | -0.99% | 2 | May 5, 2022 |
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.32
Upside: -
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $3.10
Upside: +158.06%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $3.18
Upside: +277.36%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $41.85
Upside: +14.70%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $84.22
Upside: -33.51%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.39
Upside: +308.16%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $7.84
Upside: +231.63%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $25.61
Upside: +24.95%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $14.14
Upside: -0.99%